Probatebeta
Company

PregLem

As of the edition of 20 October 2026, PregLem runs 3 drugs, 2 of them marketed; it is on route A at 3 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Family history

PregLem was acquired.

  • PregLem SA: acquired

Drugs by status

StatusCount
Marketed2
Went quiet1
Total3

Marketed drugs and when their US protection ends

DrugUS protectionRoute B rows
Ulipristal acetatenone listed0
Ulipristalnone listed0

A route B row is one company at one target.

Where it needs a new molecule

Route A at 3 targets, route B at 0 targets.

Three of its 3 rows, by target and route
TargetRoute
MAPK9 Mitogen-activated protein kinase 9Route A
MAPK10 Mitogen-activated protein kinase 10Route A
MAPK8 Mitogen-activated protein kinase 8Route A

All 3 rows on route A or B

In the product

3 company-target rows on route A or B; 0 are not shown here, and no score is.

See all 3 targets where PregLem needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.

Where its trials are

  • Pregnancy and women's health: 1 trials led
  • Urinary and reproductive: 1 trials led

Targets where PregLem has drugs

Other companies active in pregnancy and women's health